GLP-1RA users had a 37% lower risk of developing dementia compared to those on other antidiabetic drugs. Stroke risk reduced ...

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

GLP-1 RAs used by adults with type 2 diabetes and obesity is linked to lower risk for dementia, stroke, and mortality vs ...

Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their ...

Key Takeaways ・The weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer.

Benefits were most prominent among women, patients older than 60 and those with a body mass index of 30 to 40.

“Weight loss quality is a new concept….The discussion no longer revolves around the lack of adequate efficacy but rather ...

Pennington Biomedical researchers and their collaborators observed decreased activity in the brain regions responsible for ...

Thrive Health Solutions also faces a lawsuit from drugmaker Eli Lilly, for allegedly making false claims about FDA approval ...

Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type ...

Semaglutide v. tirzepatide: What to know about popular weight loss and diabetes drugs like Ozempic. By Evan MacDonald, Staff writer April 27, 2024.